Advanced drug therapy for juvenile rheumatoid arthritis.
Childhood rheumatic diseases are frequently chronic, painful, and potentially debilitating. They may adversely affect growth and development, compromise future quality of life, and contribute added stress to the patient and family. Awareness of these consequences provides a stimulus to develop more effective therapeutic regimens. There is optimism that new therapeutic strategies will result in the more widespread and earlier use of drugs, including those discussed, that may substantially impede or arrest the underlying disease.
Rosenberg
A M
AM
Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000145:classification / Q000188:drug therapy*; D002648:Child; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000962:Antimalarials; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D006046:Gold; D010396:Penicillamine; D008727:Methotrexate